Although currently underutilized, granulocyte colony-stimulating factor prophylaxis as supportive cancer care provides substantial value to society. Aligning utilization with clinical guidelines would increase this value considerably.
Alison R. Silverstein, MPH
Advertisement
Articles by Alison R. Silverstein, MPH
Advertisement
Latest Updated Articles
- The Long-term Social Value of Granulocyte Colony-Stimulating Factors
Published: October 4th 2019 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA to Restrict Ingredients Used in Mass-Marketed Compounded GLP-1s, Crack Down on Misleading Ads
2
New Legislation Aims to Address Transparency in PBMs as First Major Step in Reform
3
Overcoming Mistrust in Clinical Trial Enrollment Through Community Resources: Susan Vadaparampil, PhD, MPH
4
Catchment Areas Shape Diversity and Access in Oncology Trials: Amir Fathi, MD
5